UK markets closed

Koninklijke Philips N.V. (PHG)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
56.63+0.17 (+0.30%)
As of 3:26PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close56.46
Open56.60
Bid56.60 x 800
Ask56.62 x 1100
Day's range56.37 - 56.81
52-week range43.01 - 61.23
Volume318,139
Avg. volume618,882
Market cap51.425B
Beta (5Y monthly)0.68
PE ratio (TTM)35.98
EPS (TTM)1.57
Earnings dateN/A
Forward dividend & yield1.03 (1.83%)
Ex-dividend date10 May 2021
1y target est67.25
  • Philips announces European availability of innovations to advance personalized and efficient cardiac care at EuroPCR 2021
    Globe Newswire

    Philips announces European availability of innovations to advance personalized and efficient cardiac care at EuroPCR 2021

    Philips Azurion PCI procedure Philips Laser System Philips OmniWire Pressure Guide Wire 3D view May 18, 2021 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the European availability of new innovations in its unique portfolio of solutions that integrate imaging, devices, software, informatics and services at each point in a cardiac patient’s journey at EuroPCR 2021 (May 18-20). During the virtual event, Philips is showcasing its latest innovations in image-guided therapy that advance procedures including percutaneous coronary interventions (PCI) to treat the narrowing of coronary arteries. “At Philips we envision personalized, efficient and clinically-smart cardiac care that drives optimal outcomes throughout the patient journey,” said Bert van Meurs, Chief Business Leader for Image Guided Therapy at Philips. “At this year’s virtual EuroPCR we’re showcasing how we bring together devices, systems, software and services that improve cardiac care by strengthening clinical confidence, building efficiency throughout the care pathway and improving the experience for both patients and staff.” Philips Interventional Applications Platform – IntraSight MobileThe new Philips Interventional Applications Platform – IntraSight Mobile – brings together imaging and physiology applications on a mobile system for coronary and peripheral artery disease therapy [1]. IntraSight Mobile builds on the success of IntraSight, integrating intravascular diagnostic applications into a smart, simple, and seamless workflow solution for interventional labs. The IntraSight platform allows interventional cardiologists to perform intravascular ultrasound (IVUS) imaging and physiologic measurements of fractional flow reserve (FFR) and instant wave-free ratio (iFR) to accurately identify the location of lesions causing ischemia. IntraSight Mobile is built on the same software as IntraSight and is compatible with Philips’ current and future portfolio of IVUS and physiology disposables. It includes a touchscreen panel PC and a ruggedized multi-modality touch screen module mounted on a modern and easy to maneuver cart. Its intuitive user interface and simplified workflow offer clinicians an outstanding user experience while also optimizing lab performance. European debut of Philips OmniWire Pressure Guide WirePhilips OmniWire Pressure Guide Wire, the world’s first solid-core pressure wire for coronary artery interventions, has received CE marking and is now available in Europe [2]. With its breakthrough solid-core construction, physicians can more easily maneuver the wire in the patient’s circulatory system to measure blood pressure along the vessel and guide the delivery of catheters and stents. OmniWire supports iFR and FFR measurements, which can be co-registered onto angiograms to precisely identify the parts of a vessel that require treatment. Introduction of Philips Laser SystemThe new Philips Laser System offers plug-and-play simplicity for coronary and peripheral atherectomy procedures. The catheters compatible with the Philips Laser System are indicated in more vessel types than any other atherectomy device, and it is the only laser atherectomy technology proven for in-stent restenosis (ISR) in both coronary and peripheral vasculature [3,4]. In addition, the system is also the only laser system available for lead extraction procedures (the removal of pacemaker or defibrillator leads around the heart). Smaller, lighter and more maneuverable, the system starts up within 30 seconds and has an intuitive touch-screen interface with guided workflow prompts that minimize the need for technician training. Also being showcased at EuroPCR is the recently-introduced Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 which provides advanced hemodynamic (blood flow) measurements at the tableside in the cath lab and continuous monitoring of key vital signs throughout the patient journey. In addition, Philips Cardiovascular Imaging and Information Manager – IntelliSpace Cardiovascular – supports informed decision-making by providing a comprehensive overview of the patient’s cardiovascular care continuum and helps save time and unnecessary work and significantly improves efficiency and workflow. As demands on cardiology departments continue to increase, clinicians and administrators are balancing the delivery of high-quality care and optimal outcomes with pressure to increase efficiency and care for more patients. Definitive diagnostics, innovative procedures, and personalized patient management are essential to helping address these demands. Philips provides a unique portfolio of solutions centered on its next-generation Image Guided Therapy System – Azurion. Individually, the company’s innovations help to solve some of cardiology’s most significant daily challenges, and together they connect throughout the care pathway to create a powerful ecosystem that helps realize the vision of delivering better cardiac care with greater efficiency. For more information visit www.philips.com/cardiology. [1] Philips Mobile Interventional Applications Platform – IntraSight Mobile – is CE marked for sale in Europe and has received FDA 510(k) clearance for sale in the U.S.[2] Philips Pressure Guide Wire – OmniWire – is CE marked for sale in Europe and has received FDA 510(k) clearance for sale in the U.S.[3] Philips Laser System is CE marked for sale in Europe. The system is not currently available for sale in the U.S.[4] ISR indicated for ELCA (P002208) and the Turbo-Power (P015612) For further information, please contact: Mark GrovesPhilips Global Press OfficeTel.: +31 631 639 916E-mail: mark.groves@philips.com Fabienne van der FeerPhilips Image Guided TherapyTel: + 31 622 698 001E-mail : fabienne.van.der.feer@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Attachments Philips Azurion PCI procedure Philips Laser System Philips OmniWire Pressure Guide Wire 3D view

  • Philips introduces integrated Interventional Hemodynamic System with Patient Monitor IntelliVue X3 to improve workflow and patient focus during image-guided procedures at ACC.21
    Globe Newswire

    Philips introduces integrated Interventional Hemodynamic System with Patient Monitor IntelliVue X3 to improve workflow and patient focus during image-guided procedures at ACC.21

    Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 patient transit Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 cath lab May 14, 2021 Continuous monitoring provides informed, timely clinical decision making and comprehensive, gap-free patient records in the cath lab and beyond Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the integration of its Interventional Hemodynamic System and market-leading portable Patient Monitor IntelliVue X3, providing advanced hemodynamic (blood flow) measurements at the tableside in the cath lab and continuous monitoring of key vital signs throughout the patient journey [1]. The integration provides the opportunity for monitoring during image-guided procedures on the Philips Image Guided Therapy System – Azurion, improving workflow with comprehensive patient records that support timely clinical decision-making during interventional cardiology procedures and beyond. The solution will be introduced at ACC.21, the American College of Cardiology’s 70th Annual Scientific Session and Expo, taking place virtually on May 15-17. Health systems strive to deliver consistent quality patient care while optimizing the interventional room to treat more patients and accelerate care of the critically ill. Uninterrupted patient monitoring, as patients are moved from holding areas to the interventional room and then on to recovery areas, can help to improve clinical decision making and the timely detection of potential adverse events at every stage of the patient journey. Incorporating a 12-lead diagnostic ECG, the monitor removes the need to re-cable the patient or reconnect monitoring, and can help lead to reduced procedural preparation time, enhanced staff efficiency and ultimately an enhanced patient experience. “Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 is a unique combination made possible by our strengths in patient monitoring and image-guided therapy,” said Ronald Tabaksblat, General Manager Image Guided Therapy Systems at Philips. “Bringing advanced hemodynamic measurements to the tableside as an integrated part of our Azurion image-guided therapy system, it helps allow clinicians to assess the condition of the patient in real time during an intervention, without leaving the sterile field. It also streamlines workflows, providing continuous monitoring of the patient during every step of their care path, enhancing patient safety and confidence.” The IntelliVue X3 patient monitor can be connected to the patient from anywhere in the hospital, after which it stays with them throughout the interventional procedure, providing continuous monitoring and registration of their vital signs in the IntelliVue IT solution. After connecting the IntelliVue X3 to its docking station at the tableside of the Azurion system, clinical staff can monitor all of the patient’s vital signs including pulse oximetry end-tidal CO2, perform hemodynamic analyses and 12-lead ECG acquisitions, and relay results and waveforms from the lab’s control room to the Azurion tableside display. From the tableside the interventionalists can assess the data using the Azurion tableside Touch Screen Module, allowing them to remain focused on their patients. The system brings the latest physiological techniques to the interventional lab, including iFR (instant wave-Free Ratio) measurements, a hyperemia-free technique unique to Philips that provides valuable functional information regarding the severity of lesions in the coronary arteries. Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 integrates with Azurion, the company’s next-generation image-guided therapy system that allows clinicians to easily and confidently perform procedures with a unique user experience, helping to optimize lab performance and provide superior care. At ACC.21 Philips will showcase its solutions for the diagnosis and treatment of Structural Heart Disease, which aim to remove the barriers associated with complex procedures by helping to deliver clinical confidence where it is needed most – at the point of treatment. Philips’ cardiac care solutions help strengthen clinical confidence, build efficiency throughout the care pathway, and enhance care experiences. For more information visit www.philips.com/acc. [1] Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 is available in the majority of markets worldwide. Philips’ continuous patient monitoring solution is available for sale in markets across Europe, Middle East and APAC, with further expansion planned later this year. It is not available for sale in the U.S. For further information, please contact: Mark GrovesPhilips Global Press OfficeTel: +31 631 639 916Email: mark.groves@philips.com Anna HogrebePhilips Global Press OfficeTel.: +1 416 270 6757Email: anna.hogrebe@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Attachments Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 patient transit Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 cath lab

  • Currys is giving 1 in 20 people a free 55in TV (sort of)
    The Independent

    Currys is giving 1 in 20 people a free 55in TV (sort of)

    If you love big screens, you’ll love what the retailer has to offer